HPHA Share Price Performance
€2.77
0.02 (0.73%)
59.0% undervalued intrinsic discount
€6.75
Fair Value
Price €2.77
AnalystConsensusTarget €6.75
AnalystHighTarget €8.00
AnalystLowTarget €5.50
Fair Value€6.75
Share Pricen/a
Heidelberg Pharma AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
HPHA Community Narratives
AN
Fair Value €6.75 59.0% undervalued intrinsic discount
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value €8 65.4% undervalued intrinsic discount
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value €5.5 49.6% undervalued intrinsic discount
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Catalysts About Heidelberg Pharma Heidelberg Pharma develops antibody drug conjugates that use its proprietary Amanitin payload technology for cancer treatment. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€5.5
49.6% undervalued intrinsic discount
Fair Value
Profit Margin
5.89%
Future PE
173.33x
Price in 2029
€6.41
ATAC Platform And HDP-101 Trials Will Advance Clinical Frontiers
Key Takeaways Heidelberg Pharma's ATAC technology and multiple pipeline candidates offer potential for new revenue streams and long-term growth in earnings. Secure financial strategy through non-dilutive financing strengthens its position, supporting R&D and reducing risk.Read more
58
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
€6.75
59.0% undervalued intrinsic discount
Fair Value
Profit Margin
5.89%
Future PE
171.9x
Price in 2029
€7.8
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Catalysts About Heidelberg Pharma Heidelberg Pharma is a biotechnology company focused on developing antibody drug conjugates based on its proprietary Amanitin payload technology. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
€8
65.4% undervalued intrinsic discount
Fair Value
Profit Margin
5.89%
Future PE
126.05x
Price in 2029
€9.3
Trending Discussion
Recently Updated Narratives
AN
Single Lead ADC And Funding Risks Will Dominate Near Term But Platform Potential May Emerge
Fair Value: €5.5 49.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HPHA: Chinese Trial Milestone Will Support Future Upside From Undervalued Levels
Fair Value: €6.75 59.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Amanitin ADC Platform And ADC Market Expansion Will Support Strong Long Term Potential
Fair Value: €8 65.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Heidelberg Pharma AG Key Details
Last Reported Earnings
Nov 30, 2025
Next Reporting Earnings
Jul 15, 2026
- -0.90
- 81.31%
- -2,901.15%
- 0%
About HPHA
- Founded
- 1997
- Employees
- 114
- CEO
- WebsiteView website
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company’s lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
